PubMed Health⌕ Search

Biomedical subjects

D Sasaki

Publications and source records attributed to D Sasaki.

At least 37 records · Page 2Linked to original sources
PubMed1990

[Factors of gastric lesions following after transcatheter arterial embolization for primary hepatoma].

To clarify the influence of Transcatheter Arterial Embolization (TAE) on the stomach, endoscopic examination was carried out before and after TAE. Forty-six TAE were performed in 27 patients with primary hepatoma. New gastric lesions, erosions and ulcers, were developed in 25 of 46 TAE. There was no significant relationship between the incidence of the lesions in the cases with esophageal varices (15/24) and the cases without (10/22) and there was no significant relationship between the incidence of the lesions after the first TAE (12/22) and after the second TAE (5/14). Period between the first and the second TAE had no statistical influence on the lesions after the second TAE. Hepatic functions (Child's classification; Rmax, K, R15 of ICG; serum total protein; serum albumin; total bilirubin; prothrombin time; hepaplastin test) before TAE were not statistically related to the appearance of the gastric lesions following TAE (Table 1). On the other hand, the cases which showed apparent effects of TAE including 0.2 time decrease of AFP had the more gastric lesions (P less than 0.05) (Table 2). The cases with upper abdominal pain after TAE had more gastric lesions (24/38) than the cases without (2/8) (P less than 0.05). But the cases undergone TAE with high possibility of the influx of gelatin sponge pieces, lipiodol or anticancer agents into the supplying vessels for the stomach did not exhibit significant incidence of the lesions (Table 3). Thus, when TAE is followed by a 0.2 time decrease in AFP, it is necessary to pay more attention to the gastric lesions. The prophylactic administration of H2 antagonist before or just after TAE did not seem useful to prevent the gastric lesions. These findings suggest that the influx of gelatin sponge pieces, lipiodol or anticancer agents to the stomach does not always cause gastric ulcer or erosion.

Aged↗
PubMed1989

Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer.

We have previously reported that the combination of mitomycin C, carboquone, 5-fluorouracil and OK-432, including the intra-arterial administration of mitomycin C and carboquone (MQ-F-OK therapy), was effective in the treatment of advanced liver cancer. The Cooperative Study Group conducted a controlled study on MQ-F-OK therapy and the combination of mitomycin C, 5-fluorouracil and doxorubicin, including the intra-arterial administration of mitomycin C and doxorubicin (FAM therapy), against advanced liver cancer. Forty patients with advanced primary or secondary liver cancer were enrolled in this study and randomized into the MQ-F-OK group and the FAM group. Seventeen of the 21 cases in the MQ-F-OK group and 16 of the 19 cases in the FAM group were eligible for response evaluation in accordance with the criteria of the Japan Society for Cancer Therapy. There was no significant difference in the patient characteristics between the two groups. Three cases in the MQ-F-OK group and two in the FAM group showed partial response. There was, however, no significant difference in the response rates and the prolongation of life between the two groups. As for the side-effects, only anemia was observed more frequently in the FAM group than in the MQ-F-OK group. In conclusion, we could not preferentially recommend either MQ-F-OK therapy or FAM therapy for advanced liver cancer. The performance status of the patient was one of the most important factors in the treatment of advanced liver cancer because patients with poor performance status showed poorer results.

Adult↗
PubMed1989

[Clinical evaluation of imipenem/cilastatin sodium against severe infections complicated with hematological disorders and solid tumors].

Imipenem/cilastatin sodium (IMP/CS) was administered to patients with severe infections complicated by hematological disorders and solid tumors to assess its efficacy and safety. Primary diseases in this series of 76 cases included 37 cases of hematological disorders (acute leukemia in 25 cases, malignant lymphoma in 7 cases, aplastic anemia in 3 cases and 2 other diseases) and 38 cases of solid tumors (lung cancer in 7 cases, gastric cancer in 11 cases, esophageal cancer in 6 cases, pancreatic cancer in 3 cases, bile duct cancer in 4 cases, hepatocellular cancer in 3 cases, and 4 other diseases). Following results were obtained. 1. Types of infection in hematological diseases were sepsis in 5 cases, suspected sepsis in 24 cases, pneumonia in 5 cases and 3 others. The efficacy rates were 100% in sepsis, 62.5% in suspected sepsis, 80% in pneumonia and 73% in all cases. 2. Types of infection in solid tumors were sepsis in 2 cases, suspected sepsis in 13 cases, pneumonia in 10 cases, cholecystitis in 2 cases, cholangitis in 5 cases, liver abscess in 2 cases, and 4 others. The efficacy rates were 50% in sepsis, 69.2% in suspected sepsis, 80% in pneumonia, and 71.1% in all cases. 3. IPM/CS was administered in single use in 66 cases and in combination with other antibiotics in 9 cases. The efficacy rate in the single use was 72.7% and that in the combination use was 66.7%. 4. The efficacy rate in 35 cases of first use was 71.4% and that in 40 cases of second use was 72.5%.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1986

New method of testing for carbohydrate absorption in man. Xylose and sucrose absorption; effects of sucrase inhibition.

Absorption of carbohydrate was quantitated in 49 subjects without disease of the small bowel using a new technique for ileal perfusion. A double-lumen tube with an attached balloon was inserted retrograde through the colon and used to quantify arrival in the ileum of D-xylose and a nonabsorbable marker which had been taken orally. In the same way, absorption of sucrose and the effects of an inhibitor of alpha-glucosidase were also studied. Insertion of the assembly through the colon and intubation of the terminal ileum was usually possible within 30 min; we have designated the technique, endoscopic retrograde bowel insertion (ERBI). The test meals were 500 ml of water containing either 25 g D-xylose and 5 g polyethylene glycol (PEG 4000), or 100 g sucrose with 5 g PEG. Sucrose meals also contained 0, 100, or 200 mg of an inhibitor of alpha-glucosidase (BAYg5421). At the end of a 5-hr test period, the ratio of recovery of D-xylose relative to that of PEG indicated that 69% of D-xylose was absorbed. Five-hour urinary excretion of D-xylose was 31% of that ingested, or 45% of the D-xylose which was absorbed. Sucrose was recovered in ileal samples only when administered together with inhibitor. Rates of sucrose absorption with BAYg5421, 100 and 200 mg, were 75% and 65%, respectively. The perfusion technique of ERBI is a rapid and reproduceable approach to the distal small intestine of man which could be of value in the investigation of intestinal absorption.

Acarbose↗
PubMed1986

An endoscopic method to study the relationship between bowel habit and motility of the ascending and sigmoid colon.

Endoscopic retrograde bowel insertion (ERBI), a new method, offers rapid access to the entire colon for pressure sensors. The authors measured the pressure of both the ascending colon and the sigmoid colon and related them to the bowel habits of the subjects. The following groups were studied: control subjects, patients with diarrhea-dominant irritable bowel syndrome, patients with constipation-dominant irritable bowel syndrome, and patients with right-sided diverticular disease of the colon. In patients with irritable bowel syndrome with diarrhea or constipation, colonic motility indices (CMIs) showed a so-called "paradoxical motility" pattern. In patients with right-sided diverticular disease, the CMI was higher in the ascending colon than in the sigmoid colon. The pattern of CMIs for diverticular disease and irritable bowel syndrome varied inversely in the ascending colon and in the sigmoid colon with diarrhea and constipation. These results suggest that the mechanisms of altered bowel habits in patients with these diseases are quite different.

Adolescent↗
PubMed1986

Investigation of regional differences in water and electrolyte absorption across the human colon by in vivo perfusion method.

Colonic perfusion studies were performed to evaluate regional differences in water and electrolyte absorption across the human colon. In 19 healthy male volunteers, a 5-lumen tube with two balloons was inserted into the colon by the endoscopic retrograde bowel insertion (ERBI) method and a 25 cm segment of either the right or the left colon was perfused with an isotonic electrolyte solution simulating the fasting ileal content at a rate of 5 ml/min. Additionally into 5 subjects of the right colon and 5 subjects of the left colon, PSP solution was injected and mean transit time was calculated by the dilution method. Higher absorption rates of water, Na and Cl were observed in the right than in the left colon. Mean transit time was longer in the left than in the right colon. It was considered that the right colon had greater absorptive capacity than the left. The colonic perfusion study by the use of ERBI method made it possible to determine the absorption of water and electrolytes in the right and left colon directly in man, and would be useful to elucidate the pathophysiology of colonic diarrhea.

Adolescent↗
PubMed1986

[Chemoembolization therapy with cisplatin.lipiodol (CDDP.lipiodol) in primary liver cancer--with special reference to hepatocellular carcinoma].

From Jan., 1985 to Mar., 1986 thirty-six patients with primary liver cancer received transcatheter arterial chemoembolization therapy with Cisplatin (100 mg) blended into Lipiodol (5 ml) and simple embolization therapy with Gelfoam particles. Thirty-three cases out of 36 had hepatocellular carcinoma, one had hepatoblastoma and one had adenocarcinoma. Ten (31%) out of 32 had hepatocellular carcinoma, and showed objective tumor reduction greater than 50% (partial response) regarding the main tumor. Of the 33 there was one sudden death due to intracerebral hemorrhage. Only two out of 25 cases with daughter nodules showed slight reduction. Almost all cases with daughter nodules showed no response to chemoembolization therapy. Five patients died after chemoembolization therapy during the fifteen-month study period. Two patients died of liver abscess or cholecystitis and surrounding abscess, one died of intracerebral hemorrhage, one died of hepatic failure and the remaining case was one of tumor death.

Carcinoma, Hepatocellular↗
PubMed1985

Treatment of irritable bowel syndrome with prifinium bromide.

Prifinium bromide, an anticholinergic agent, was given to patients with irritable bowel syndrome in an open trial to evaluate the drug's clinical efficacy. The trial lasted four weeks, although two of the 40 patients were treated for only two weeks. Prifinium bromide was judged beneficial in 28 patients (70%), slightly beneficial in six (15%), and not beneficial in six (15%). One case of moderate constipation was the only side effect encountered. In conclusion, prifinium bromide is considered a valuable drug for the management of irritable bowel syndrome.

Adolescent↗
PubMed1984

Effect of antispasmodic drugs on colonic motility. Part I: Laboratory study of the dog.

The inhibitory effect of five antispasmodic preparations, prifinium bromide, hyoscine butylbromide, propinox, trimebutine maleate and phloroglucinol + trimethyl-phloroglucinol on acetylcholine-induced contraction of the colon was investigated in anesthetized dogs. Prifinium bromide was most potent followed by hyoscine butylbromide. The other three preparations had no potent inhibitory effect even when given in a dose of 1000 micrograms/kg. The ED50 was 3.1 micrograms/kg for prifinium bromide and 12.3 micrograms/kg for hyoscine butylbromide; the prolonged time of action at ED50 was approximately 30 minutes for prifinium bromide and about 10 minutes for hyoscine butylbromide. From the dog experiments, it became clear that prifinium bromide and hyoscine butylbromide had a relatively potent antispasmodic effect on the colon.

Acetylcholine↗
PubMed1984

Effect of antispasmodic drugs on the colonic motility. Part II: Clinical study in man.

Four antispasmodic preparations (prifinium bromide, propinox, trimebutine maleate and phloroglucinol + trimethylphloroglucinol) identical to those in Part I, study of the dog, were used. Eight subjects were tested for each preparation and eight subjects for the control. The inhibitory effect of the test preparations on neostigmine-induced hypermotility of the ascending and sigmoid colons were investigated. Prifinium bromide provided a marked antispasmodic effect on the ascending and sigmoid colons; the inhibitory effect of trimebutine maleate was limited to the ascending colon. Propinox and phloroglucinol + trimethylphloroglucinol possessed no clear action. It is estimated that prifinium bromide may be useful in the control of the manifestic state of hypermotility of the colon.

Adult↗
PubMed1981

Anti-spasmodic effect of prifinium bromide on the proximal and distal colon in patients with diverticular disease.

In 5 patients with diverticular disease, colonic motilities of the proximal and distal colon were recorded using the ERBI method. The motilities were studied during resting, after prostigmin 0.5 mg i.m. injection and after prifinium bromide 7.5 mg i.m. injection, with the following results: After prostigmin colonic motility of the proximal colon became significantly greater than that of the distal colon. Prifinium bromide inhibited the prostigmin-induced hypermotility markedly. It was demonstrated that this drug has an antispasmodic action not only on the distal colon but also on the proximal colon. Prifinium bromide was an antispasmodic drug which brought about a rapid effect which appears within 3 minutes after injection. The effect persisted for about 1 hour.

Colon↗